Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Capital Expenditures (2019 - 2025)

Revolution Medicines has reported Capital Expenditures over the past 7 years, most recently at $454000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $454000.0 for Q4 2025, down 95.32% from a year ago — trailing twelve months through Dec 2025 was $1.9 million (down 81.8% YoY), and the annual figure for FY2025 was $1.9 million, down 81.8%.
  • Capital Expenditures for Q4 2025 was $454000.0 at Revolution Medicines, up from -$1.5 million in the prior quarter.
  • Over the last five years, Capital Expenditures for RVMD hit a ceiling of $9.7 million in Q4 2024 and a floor of -$5.0 million in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $1.2 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Capital Expenditures: soared 2314.29% in 2021 and later plummeted 606.13% in 2024.
  • Revolution Medicines' Capital Expenditures stood at $1.2 million in 2021, then surged by 581.49% to $8.1 million in 2022, then decreased by 20.62% to $6.4 million in 2023, then soared by 51.44% to $9.7 million in 2024, then crashed by 95.32% to $454000.0 in 2025.
  • The last three reported values for Capital Expenditures were $454000.0 (Q4 2025), -$1.5 million (Q3 2025), and $122000.0 (Q2 2025) per Business Quant data.